UnitedHealth Group Inc (UNH) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

UnitedHealth Group Inc (UNH)

424.72

-3.47 (0.81%)

as of Jul 8, 2026, 10:00:07 pm Market Open.

288 watching

Investor Insights

Jul 8, 2026, 12:00 am

This summary was created by AI, based on 41 opinions in the last 12 months.

UnitedHealth Group Inc (UNH) faces a complex set of challenges and opportunities as experts express mixed sentiments about its future. On one hand, there is optimism regarding its recovery potential, driven by leadership changes, historical success, and potential growth in earnings as medical costs stabilize. However, many analysts are concerned about sustained pressures from regulatory scrutiny, rising healthcare costs, and shifts in Medicare policies. While some see it as a defensive play with the potential for significant upside, others caution against investing due to a reputation for volatility and uncertain future prospects. Analysts point to a strong reliance on US federal funding and highlight the impact of broader economic factors affecting the healthcare sector overall.

Consensus

Mixed

Valuation

Undervalued

Similar

CVS

TOP PICK

The US is talking about having Medicare for all. This company does a good job of eliminating cost for all involved. They raised the dividend over the last few years. He sees it as a good solid company. (Analysts’ price target is $287.80)

PAST TOP PICK

(A Top Pick Mar 11/19, Up 2%) Really good day trade. Not a happy place to be as a retail investor. Not something you need to own right away. Chart's gone straight up for so long, but now facing some turbulence. Now it's a hold or a watch.

TOP PICK

They are the largest Health Care provider in the US. He thinks it is going back into the $300 territory after the election. P/E is 17. (Analysts’ price target is $287.72)

DON'T BUY

Basically an insurance provider. Healthcare space in general is messy. Trump is attacking healthcare companies. Insurance costs are rising, but they can't keep going up when wages aren't increasing. So insurance is trying to move down the food chain. Plus, Amazon is getting into the business. He'd be really nervous.

TOP PICK

A managed care company. Like a large medical insurance company, but they own their own facilities and networks. A shock when it sold off. Valuation is fantastic. Once in a decade buying opportunity. Yield is 1.55%. (Analysts’ price target is $288.54)

BUY

Trading at 17 times forward earnings. 13-14% growth rate. 1.5% dividend yield. 15 billion dollar worth of free cash flow. They are in pharmacy and benefit management service. They are have scale across different segments. Good for an uncertain time despite the politics.

BUY ON WEAKNESS

Good operator. Sensible balance sheet. Like the "Home Depot" of healthcare. Difficult to buy on price. Well run. Always at a premium price, as it's a good company.

TOP PICK

Just tested the 50- and 100-week moving averages--and hasn't broken them. It's still cheap after selling off, building a base and is now moving up.

WAIT

Start a position at $240? Positives: top-shelf management with a history of returning 50% of free cash flow each year through dividends and stock buys. They're massive and have cost advantage. Cons: in consolidation now. He takes a longer view on UNH, but wouldn't buy it now. There's no rush to. UNH is also beta. Numbers solid, but UNH isn't cheap. Watch it.

BUY

On a 12 months basis it is better than 85% of the companies in the NYSE. Healthcare has come back quite nicely. This is trading well above a rising 150 day average. This is a theme you can depend on. Managed Healthcare. Continue to hold it.

BUY ON WEAKNESS

It has characteristics of a defensive nature but grows at double digit earnings each year. There are headwinds in that space. Amazon may be entering the pharmacy business. But people are living longer and will need health care longer. Buy it on dips.

COMMENT

18X foward earnings. ROE is 20% average over 5 five years. Healthcare gies you (Analysts’ price target is $301.58)

TOP PICK

It's #5 in revenue of all US companies. They'll do $250 billion in revenue in 2019. It's down only 7-8% during this market carngage, so it's held its own. The CEO belives they just started a growth boom. Has a good runway ahead, working closely with government agencies and in South America. Good defensive stock. (Analysts’ price target is $304.74)

WATCH

They are just so consistent. The health care sector is just so influenced by politics. But these guys reduce costs for governments. This stock has been spectacular. They have scale and a phenomenal management team that returns capital to shareholders. He would not buy more at this time.

BUY

Looks very strong. The technical strength is strong. PEG ratio is 1.4. Likes it. Longer term, 1 year, 24 months this is a good place to be.

Showing 196 to 210 of 287 entries

Most Recent Experts

Rebecca Teltscher

Newhaven Asset Management

Ernest Wong, Head of Research, Baskin Wealth Management

Baskin Wealth Management

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Jim Cramer - Mad Money

CNBC

Kim Bolton

Black Swan Dexteritas

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

UnitedHealth Group Inc (UNH)